Replies to post #182238 on Biotech Values

[oldberkeley]

ACST Just got murdered with this one, sold in PM for a substantial loss.

Yep, I agree about the AMRN factor. Perhaps the market is just not excited in general about fish/krill oil products, seems too low-tech.

[Dancing in the dark]

with the Waksal ties, is there Acasti/Kadmon Capre Phase iii partnership in the making? Kadmon is already has another drug candidate in the dyslipidemia space.